The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, OptumRx and Express Scripts.

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" prescription price hikes of 1,000% or more.

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from price gouging.

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at their pharmacies by hundreds or thousands of percent.

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their prices by hundreds — and in some cases, thousands — of percent, resulting in $7.3 billion in revenue above cost.

Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion in revenue, The Federal Trade Commission (FTC) said in a report released today.

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report examines the impact of PBMs (specifically CVS Caremark, Express Scripts and Optum Rx) on specialty generic drugs,

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging margins.

Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs,

The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

EXCLUSIVE: In his only newspaper interview during his trip to Washington, Nigel Farage says Donald Trump is the 'most Anglophile president' in 64 years. Ukraine has launched devastating strikes on ...

The global prescription delivery service market is poised for steady growth, with its valuation projected to increase from USD 165.4 million in 2024 to USD 287.9 million by 2034, reflecting a compound annual growth rate (CAGR) of 5.7% over the forecast period.